Statins

1. Rosuvastatin decreases endoglin in humans.

   “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

   Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

   The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

2. Atorvastatin decreases endoglin in humans.

   “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

   Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

   The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

Endoglin →

1. Rosuvastatin decreases endocan in humans.

   “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

   Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

   The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

2. Atorvastatin decreases endocan in humans.

   “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

   Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

   The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study · Biomedicines · 27 Aug 2026

Endocan →

1. Statins have no effect on non-liver-related death in humans (HR 0.499, 95% CI 0.224-1.111).

   Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

   Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis · European journal of internal medicine · 3 Oct 2026

1. Statins decrease liver-related death in humans (HR 0.076, 95% CI 0.010-0.584).

   Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

   Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis · European journal of internal medicine · 3 Oct 2026

1. Statins decrease mortality in humans (HR 0.318, 95% CI 0.153-0.661).

   Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

   Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis · European journal of internal medicine · 3 Oct 2026

1. Statins improve cirrhosis-free survival in humans (HR 0.139, 95% CI 0.041-0.467).

   Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

   Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis · European journal of internal medicine · 3 Oct 2026

1. Statins decrease LDL cholesterol in humans (donut estimates vary from - 1.00 to - 1.72 mmol/L).

   Humansaround the first recorded prescription date

   Event-time regression discontinuity for biomedical data: LATT estimation and covariate distribution tests · American journal of epidemiology · 29 Sep 2026

LDL cholesterol →

1. Statins have no effect on cancer-related mortality in humans.

   Humanswithout CHD

   Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease · Archives of gerontology and geriatrics · 22 Sep 2026

1. Statins decrease amputation severity in humans (aOR 0.43, 95% CI 0.20-0.74).

   Humansdiabetic foot infectionmoderate-intensity

   The impact of statin therapy on amputation risk in patients with diabetic foot infection: a retrospective cohort study from Jordan · Frontiers in endocrinology · 16 Sep 2026

1. Atorvastatin has no effect on major adverse cardiovascular events in humans.

   Human trialnoncardiac surgery in patients with RCRI >= 180 mg24 hours preoperatively

   The Effect of High-Dose Atorvastatin on Postoperative Troponin in Patients Undergoing Non-Cardiac Surgery: A Triple-Blind Randomized Clinical Trial · Research in heart yield and translational medicine · 1 Jan 2025

1. Statins lower the risk of mortality in humans (52.0% vs. 72.8%).

   Humanswith CHD

   Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease · Archives of gerontology and geriatrics · 22 Sep 2026

2. Statins lower the risk of mortality in humans.

   Humanscritically ill ischemic stroke patients

   Statins link to lower mortality in critical stroke patients · Frontiers in aging neuroscience · 15 Sep 2026

1. Statins lower the risk of hepatic decompensation in humans (0.4% vs 4.7%).

   Humansin non-cirrhotic patients with primary biliary cholangitisn = 507

   Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis · European journal of internal medicine · 3 Oct 2026

Hepatic decompensation →

1. Statins are associated with Barthel index in humans (mean difference 5.58 points, 95% CI 0.44 to 10.7).

   Human trialexercise during acute hospitalizationn = 310

   Statin use and functional response to multicomponent exercise in acutely hospitalized older adults: secondary analysis of a randomized trial · European geriatric medicine · 30 Sep 2026

Barthel index →

1. Statins lower the risk of retinal vein occlusion in humans (OR = 0.65 (95% CI = 0.53-0.79)).

   Reviewmeta-analysis of observational studies

   Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis · Eye (London, England) · 24 Sep 2026

Retinal vein occlusion →

1. Statins lower the risk of cancer-related mortality in humans (11.5% vs. 18.0%).

   Humanswith CHD

   Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease · Archives of gerontology and geriatrics · 22 Sep 2026

1. Statins lower the risk of cardiac mortality in humans (18.3% vs. 25.9%).

   Humanswith CHD

   Trends in statin use and its association with mortality among older U.S. cancer survivors with and without coronary heart disease · Archives of gerontology and geriatrics · 22 Sep 2026

1. Statins lower the risk of major amputation in humans (ARR 9.3%).

   Humansdiabetic foot infectionmoderate-intensity

   The impact of statin therapy on amputation risk in patients with diabetic foot infection: a retrospective cohort study from Jordan · Frontiers in endocrinology · 16 Sep 2026

1. Pitavastatin lowers the risk of cardiovascular events in humans.

   “In the REPRIEVE study, treatment with pitavastatin was shown to reduce the rate of first cardiovascular events among individuals with HIV receiving antiretroviral therapy.”

   Reviewreceiving antiretroviral therapy

   Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE · Biomolecules · 29 Aug 2026

Cardiovascular events →

1. Statins lower the risk of dementia in humans (-15% relative risk (95% CI 9%-21%)).

   Humanswithin ≤ 1 year after type 2 diabetes diagnosis vs no statin within 5 years10 years

   Early statin use links to lower dementia risk in diabetes · The Lancet regional health. Europe · 27 Aug 2026

Dementia →

1. Statins raise the risk of thyroid cancer in humans.

   Humans≥6 months

   Statin Use and Site-Specific Cancer Risk: A Nationwide Cohort Study Using Korean Health Insurance Data · Journal of lipid and atherosclerosis · 12 Jun 2026

Thyroid cancer →